These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults. McMahon D; Lederman M; Haas DW; Haubrich R; Stanford J; Cooney E; Horton J; Kelleher D; Ross L; Cutrell A; Lee D; Spreen W; Mellors JW Antivir Ther; 2001 Jun; 6(2):105-14. PubMed ID: 11491415 [TBL] [Abstract][Full Text] [Related]
6. New expanded access drugs for use in combination therapy. Notes Undergr; 1998; (No 37):suppl 1-2. PubMed ID: 11365823 [TBL] [Abstract][Full Text] [Related]
7. Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment. Rozenbaum W; Katlama C; Massip P; Bentata M; Zucman D; Delfraissy JF; Trepo C; David F; Lanier ER; Vavro C; Mamet JP Antivir Ther; 2001 Jun; 6(2):135-42. PubMed ID: 11491418 [TBL] [Abstract][Full Text] [Related]
9. New drugs: amprenavir and abacavir. TreatmentUpdate; 1998 Apr; 10(2):3-4. PubMed ID: 11365435 [TBL] [Abstract][Full Text] [Related]
10. Once-daily abacavir in place of twice-daily administration. Goedken AM; Herman RA Ann Pharmacother; 2005; 39(7-8):1302-8. PubMed ID: 15956231 [TBL] [Abstract][Full Text] [Related]
11. Early intensification with abacavir in subjects at high risk for incomplete viral suppression. Bartlett JA; Tebas P; Bassett R; Huang W; Kuritzkes D; Reisler R; Loyack N; Robison K; Antivir Ther; 2003 Aug; 8(4):361-3. PubMed ID: 14518706 [No Abstract] [Full Text] [Related]
12. Vertigo and abacavir. Fantry LE; Staecker H AIDS Patient Care STDS; 2002 Jan; 16(1):5-7. PubMed ID: 11839213 [TBL] [Abstract][Full Text] [Related]
13. [Observational study with abacavir. Decreased viral load and quality of life improves]. MMW Fortschr Med; 2001 Apr; 143 Suppl 1():52-3. PubMed ID: 11373782 [No Abstract] [Full Text] [Related]
14. Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated encephalopathy. Saavedra-Lozano J; Ramos JT; Sanz F; Navarro ML; de José MI; Martín-Fontelos P; Mellado MJ; Leal JA; Rodriguez C; Luque I; Madison SJ; Irlbeck D; Lanier ER; Ramilo O Pediatr Infect Dis J; 2006 Dec; 25(12):1142-52. PubMed ID: 17133160 [TBL] [Abstract][Full Text] [Related]
15. Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backbone. Moyle GJ AIDS Read; 2003 Nov; 13(11):528, 533-5. PubMed ID: 14649622 [No Abstract] [Full Text] [Related]
16. Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects. King D; Tomkins S; Waters A; Easterbrook PJ; Thurmond LM; Thorborn DE; Raffi F; Kemeny DM; Vyakarnam A J Allergy Clin Immunol; 2005 May; 115(5):1081-7. PubMed ID: 15867870 [TBL] [Abstract][Full Text] [Related]
17. Ziagen (abacavir) approved: caution essential. James JS AIDS Treat News; 1999 Jan; (No 310):1, 3-6. PubMed ID: 11366148 [TBL] [Abstract][Full Text] [Related]
18. Abacavir at last. Gilden D GMHC Treat Issues; 1998 Mar; 12(3):9. PubMed ID: 11365394 [TBL] [Abstract][Full Text] [Related]
19. Generic lamivudine and abacavir approved. AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043839 [No Abstract] [Full Text] [Related]